Suven Life Sciences Financial Results
- Market cap
- ₹8,098 crore
- P/E
- 22.5
- P/B
- 13.69
- ROE
- -78.8%
- Dividend yield
- 1.20%
For the year ended Mar 2019, Suven Life Sciences reported revenue of and net profit of ₹87 crore, against and -₹94 crore a year earlier.
Suven Life Sciences annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 6 | 16 | 6 | 4 | — |
| Expenses | — | — | — | — | 132 | 118 | 168 | 284 | — |
| Operating profit | — | — | — | — | — | — | — | — | — |
| Operating margin % | — | — | — | — | — | — | — | — | — |
| Other income | — | — | — | — | 8 | -4 | 1 | 3 | 9 |
| Interest | 4 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 22 | 4 | 4 | 4 | 7 | 7 | 6 | 6 | 6 |
| Profit before tax | 159 | -106 | -77 | -122 | -118 | -106 | -161 | -276 | -352 |
| Tax % | 45% | 11% | 7% | 0% | 0% | 1% | 0% | 0% | 0% |
| Net profit | 87 | -94 | -72 | -122 | -118 | -105 | -161 | -276 | -352 |
| EPS (₹) | 3.99 | -4.32 | 0.00 | 0.00 | -5.42 | -4.82 | -7.37 | -10.48 | -13.36 |
| Dividend payout % | — | — | — | — | — | — | — | — | — |
Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Suven Life Sciences financial results — frequently asked questions
What is the EPS of Suven Life Sciences?
Annual EPS for Mar 2019 was ₹3.99.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Suven Life Sciences With ATS
Track SUVEN live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.